[{"orgOrder":0,"company":"Cytora Therapeutics","sponsor":"Made Scientific","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2026","type":"Collaboration","leadProduct":"hOMSC200","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cytora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytora Therapeutics \/ Made Scientific | ZEO ScientifiX","highestDevelopmentStatusID":"6","companyTruncated":"Cytora Therapeutics \/ Made Scientific | ZEO ScientifiX"}]

Find Clinical Drug Pipeline Developments & Deals by Cytora Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : The collaboration aims to advance hOMSC200, a Cell & Gene Therapy, for non-healing Diabetic Foot Ulcers.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          January 07, 2026

                          Lead Product(s) : hOMSC200

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Made Scientific

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank